Cloud-clone
SKU(재고 관리 코드):LMB817Hu
Magnetic Luminex Assay Kit for Versican (VCAN) ,etc.
Magnetic Luminex Assay Kit for Versican (VCAN) ,etc.
Product No.
LMB817Hu
Organism Species
Homo sapiens (Human).
Sample Type
Serum, plasma, tissue homogenates and other biological fluids
Test Method
Double-antibody Sandwich
Assay Length
3.5h
Detection Range
4.88-5000pg/mL
Sensitivity
The minimum detectable dose of this kit is typically less than 1.627 pg/mL.
UOM
1Plex 2Plex 3Plex 4Plex 5Plex 6Plex 7Plex 8Plex
Specificity
This assay has high sensitivity and excellent specificity for detection of Versican (VCAN) ,etc..
No significant cross-reactivity or interference between Versican (VCAN) ,etc. and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Versican (VCAN) ,etc. and the recovery rates were calculated by comparing the measured value to the expected amount of Versican (VCAN) ,etc. in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 83-101 | 93 |
| EDTA plasma(n=5) | 79-91 | 83 |
| heparin plasma(n=5) | 92-99 | 96 |
| sodium citrate plasma(n=5) | 79-104 | 86 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Versican (VCAN) ,etc. were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Versican (VCAN) ,etc. were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Versican (VCAN) ,etc. and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 84-104% | 85-98% | 81-105% | 88-98% |
| EDTA plasma(n=5) | 87-102% | 80-97% | 93-101% | 94-101% |
| heparin plasma(n=5) | 91-99% | 97-104% | 89-98% | 86-103% |
| sodium citrate plasma(n=5) | 78-92% | 95-102% | 87-95% | 92-101% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:VCAN) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
| Magazine | Citations |
| Plos one | Tumor-Produced Versican V1 Enhances hCAP18/LL-37 Expression in Macrophages through Activation of TLR2 and Vitamin D3 Signaling to Promote Ovarian Cancer Progression In Vitro PubMed: PMC3570526 |
| Clinica Chimica Acta | Versican and its associated molecules: Potential diagnostic markers for multiple myeloma Pubmed:25623955 |
| Journal of Cancer Research and Clinical Oncology | Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma |
| RNA Biology | Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signaling Pubmed: 31532704 |
| miR-124-3p and miR-181a-5p Mediate AT1-Receptor Autoantibody Induced Fetal Rat Cardiac Remodeling via Increased VCAN Expression |
| Catalog No. | Related products for research use of Homo sapiens (Human) Organism species | Applications (RESEARCH USE ONLY!) |
| RPB817Hu02 | Recombinant Versican (VCAN) | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPB817Hu01 | Recombinant Versican (VCAN) | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB817Hu01 | Polyclonal Antibody to Versican (VCAN) | WB,IHC |
| PAB817Hu02 | Polyclonal Antibody to Versican (VCAN) | WB; IHC; ICC; IP. |
| MAB817Hu22 | Monoclonal Antibody to Versican (VCAN) | WB; IHC; ICC; IP. |
| SEB817Hu | ELISA Kit for Versican (VCAN) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCB817Hu | CLIA Kit for Versican (VCAN) | Chemiluminescent immunoassay for Antigen Detection. |
| LMB817Hu | Magnetic Luminex Assay Kit for Versican (VCAN) ,etc. | Magnetic Luminex Assay for Antigen Detection. |
Share
